

Designs under Discussion for "Unmet Prevention Need"

Ideas emerging from Seattle Workshop "HIV Prevention Efficacy Trial Designs of the Future" Nov 5, 2018

Deborah Donnell

HPTN SDMC PI, Fred Hutch, Seattle
June 2019



Goal: Regulatory Approval of New Product

1. Safe

Sufficient total person years of experience Safety established with 12+ months of use

2. Effective


Unequivocal evidence of prevention of HIV infection


Standard for evidence

- Randomized Clinical Trial
- In populations at highest need

Current Era: FTC/TDF PrEP

- Current approved market leader is highly effective
- Dependent on daily adherence to pill taking







Data accumulating about PrEP non-persistence

HPTN 067: < 2 pills/week (daily arm)

At 30 weeks

Young women in Capetown: 46%

• MSM in Thailand: 4%

• MSM in Harlem, US: 50%

• HPTN 073: < 4 days/week

• Black MSM at 26 weeks: 36%

HPTN 082: Undetectable DBS at 13 weeks

• Young women in Africa: 16%

US PrEP user pharmacy refills (Coy, 2019, JAIS)

• At year 1 44%

• At year 2 37%



With an effective product, three choices in future RCTs

1. Compare

Compare experimental product (EXP) to existing prevention (FTC/TDF)

HPTN 083/084







EXP

2. Layer

Compare EXP to placebo (PBO) on top of use of existing prevention

AMP



3. Combine


Compare existing prevention combined with EXP product



FTC/TDF+ Placebo



FTC/TDF + EXP





Potential PrEP initiation new approach PrEP success? Yes No Continue PrEP R Placebo **PrEP EXP** PrEP access




Sample size implications

- Incidence in those with unmet need is probably higher
- Difference between incidence placebo and active is projected to be bigger

Percentage on PrEP	Type: Powered for 60% efficacy of EXP	Total number of infections	Number of participants (Assuming 4% incidence)
100%	Non-inferiority	980	17,754
75%	Non-inferiority	192	3,033
50%	Superiority	196	2,745
25%	Superiority	104	1,308
0%	Superiority	70	799

Potential new approach





Explore innovative design ideas

- Challenge of advancing new products for prevention when existing products are very successful
- Need community, stakeholder and scientists engaged in robust discussion of prevention need, to discern a path forward together